BioCentury

7:00 AM GMT, Sep 6, 2010
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Deals

Genzyme, sanofi-aventis deal

Genzyme rejected an unsolicited offer from sanofi-aventis to acquire the company for $69 per share in cash, or about $18.5 billion. The

Read the full 222 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.